CL097

CL097, a potent TLR7 and TLR8 agonist, induces pro-inflammatory cytokines in macrophages CL097 induces NADPH oxidase priming, resulting in an increase of the fMLF-stimulated ROS production . In Vitro CL097 induces activation of NF-κB at 0.1 μM in TLR7 transfected HEK293 cells and at 4 μM in TLR8-transfected HEK293 cells. CL097 induces hyperactivation of the NADPH oxidase by stimulating the phosphorylation of p47phox on selective sites in human neutrophils and suggest that p38 MAPK, ERK1/2, protein kinase C, and Pin1 control this process. CL097 induces the phosphorylation of p47phox on specific sites and enhances fMLF-induced p47phox phosphorylation. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: Neutrophils Concentration: 0, 0.5, 2.5, 5, and 10 μg/mL Incubation Time: Pretreated for 30 minutes Result: Induced phosphorylation of p47phox on specific sites in a concentration-dependent manner. In Vivo CL097 and CD40 agonist stimulation induces efficient diabetogenic Cytotoxic T lymphocyte (CTL) function in NOD mice. CL097 (5 mg/kg, s.c.) alone causes a modest specific lysis of the target peptide (∼25%). However, treatment with a combination of CL097 and CD40 agonist (10 mg/kg, i.p.) results in an increase of approximately twofold in the specific lysis of the IGRP-peptide-coated targets compared with CL097 treatment alone. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female 8.3 NOD mice (5-6 weeks old)Dosage: 5 mg/kg Administration: Injected s.c. Result: Caused a modest specific lysis of the target peptide (∼25%). Form:Solid IC50& Target:TLR7 TLR8

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet